Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer

The new Tesaro ovarian cancer drug will be marketed under the brand name Zejula.

XBiotech Silent as Deadline for European Resubmission of Colon Cancer Drug Passes

XBiotech Silent as Deadline for European Resubmission of Colon Cancer Drug Passes

The XBiotech drug, Xilonix, had no effect on the size of colon cancer tumors with zero complete or partial responses reported in the phase III study.

Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO

Alexion Pharma, Still Recovering From Boardroom Troubles, Appoints New CEO

Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion.

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.